89bio Inc (ETNB)
8.75
-0.16
(-1.85%)
USD |
NASDAQ |
Nov 14, 16:00
8.50
-0.25
(-2.86%)
After-Hours: 20:00
89bio Cash from Investing (Quarterly): -8.639M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -8.639M |
| June 30, 2024 | 27.85M |
| March 31, 2024 | -79.90M |
| December 31, 2023 | -63.64M |
| September 30, 2023 | 38.33M |
| June 30, 2023 | -101.81M |
| March 31, 2023 | 4.106M |
| December 31, 2022 | -11.06M |
| September 30, 2022 | -42.06M |
| June 30, 2022 | -7.596M |
| March 31, 2022 | 26.77M |
| December 31, 2021 | 19.09M |
| Date | Value |
|---|---|
| September 30, 2021 | 17.36M |
| June 30, 2021 | -13.88M |
| March 31, 2021 | -15.41M |
| December 31, 2020 | -29.03M |
| September 30, 2020 | -72.00M |
| June 30, 2020 | -5.744M |
| March 31, 2020 | -0.061M |
| December 31, 2019 | -0.111M |
| September 30, 2019 | -0.008M |
| June 30, 2019 | -0.018M |
| March 31, 2019 | -0.002M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-101.81M
Minimum
Jun 2023
38.33M
Maximum
Sep 2023
-15.87M
Average
-8.118M
Median
Cash from Investing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -202.39M |
| Eli Lilly and Co | -4.005B |
| Viking Therapeutics Inc | 25.90M |
| Akero Therapeutics Inc | 73.07M |
| NovaBay Pharmaceuticals Inc | -0.002M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -145.36M |
| Cash from Financing (Quarterly) | 33.19M |
| Free Cash Flow | -280.54M |
| Free Cash Flow Per Share (Quarterly) | -1.358 |
| Free Cash Flow Yield | -33.44% |